DE60223688D1 - Verfahren zur behandlung von multiplem myelom - Google Patents

Verfahren zur behandlung von multiplem myelom

Info

Publication number
DE60223688D1
DE60223688D1 DE60223688T DE60223688T DE60223688D1 DE 60223688 D1 DE60223688 D1 DE 60223688D1 DE 60223688 T DE60223688 T DE 60223688T DE 60223688 T DE60223688 T DE 60223688T DE 60223688 D1 DE60223688 D1 DE 60223688D1
Authority
DE
Germany
Prior art keywords
treatment
multiple myeloma
myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223688T
Other languages
English (en)
Other versions
DE60223688T2 (de
Inventor
Robert Lindsay Raison
Rosanne Dorothy Dunn
Boon Hwa Andre Choo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNE SYSTEMS THERAPEUTICS Ltd
Immune System Therapeutics Ltd
Original Assignee
IMMUNE SYSTEMS THERAPEUTICS Ltd
Immune System Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNE SYSTEMS THERAPEUTICS Ltd, Immune System Therapeutics Ltd filed Critical IMMUNE SYSTEMS THERAPEUTICS Ltd
Application granted granted Critical
Publication of DE60223688D1 publication Critical patent/DE60223688D1/de
Publication of DE60223688T2 publication Critical patent/DE60223688T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60223688T 2001-07-06 2002-07-05 Verfahren zur behandlung von multiplem myelom Expired - Lifetime DE60223688T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR6179A AUPR617901A0 (en) 2001-07-06 2001-07-06 Method for treating multiple myeloma
AUPR617901 2001-07-06
PCT/AU2002/000896 WO2003004056A1 (en) 2001-07-06 2002-07-05 Method for treating multiple myeloma

Publications (2)

Publication Number Publication Date
DE60223688D1 true DE60223688D1 (de) 2008-01-03
DE60223688T2 DE60223688T2 (de) 2008-10-30

Family

ID=3830143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223688T Expired - Lifetime DE60223688T2 (de) 2001-07-06 2002-07-05 Verfahren zur behandlung von multiplem myelom

Country Status (13)

Country Link
US (3) US7344715B2 (de)
EP (1) EP1414492B1 (de)
JP (1) JP4535424B2 (de)
CN (1) CN1551783B (de)
AU (1) AUPR617901A0 (de)
CA (1) CA2461989C (de)
DE (1) DE60223688T2 (de)
DK (1) DK1414492T3 (de)
ES (1) ES2296952T3 (de)
MX (1) MXPA04000130A (de)
NZ (1) NZ530099A (de)
WO (1) WO2003004056A1 (de)
ZA (1) ZA200400959B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
CA2557482C (en) * 2004-02-27 2018-01-16 Pacmab Limited Target for b-cell disorders
EP2237041A1 (de) * 2004-12-23 2010-10-06 F. Hoffmann-La Roche AG Nachweis eines therapeutischen Antikörpers in einem Versuchstier
GB0608444D0 (en) * 2006-04-27 2006-06-07 Binding Site The Ltd Dialysis
HUE031944T2 (en) 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN102596997B (zh) 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CA3043423A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US10238690B2 (en) 2013-03-15 2019-03-26 Celgene Corporation Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
NZ735778A (en) 2015-04-23 2024-03-22 Haemalogix Pty Ltd Kappa myeloma antigen chimeric antigen receptors and uses thereof
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
ES2916335T3 (es) 2016-10-20 2022-06-30 Celgene Corp Receptores de antígeno quimérico heterodimerizable basados en cereblon
JP2023085151A (ja) * 2021-12-08 2023-06-20 株式会社八神製作所 体外ホウ素中性子反応を用いた幹細胞の分取方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AUPR617901A0 (en) * 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma

Also Published As

Publication number Publication date
EP1414492B1 (de) 2007-11-21
ES2296952T3 (es) 2008-05-01
DK1414492T3 (da) 2008-04-07
CA2461989C (en) 2011-11-15
US7838041B2 (en) 2010-11-23
MXPA04000130A (es) 2005-06-06
JP2005504018A (ja) 2005-02-10
AUPR617901A0 (en) 2001-08-02
EP1414492A4 (de) 2005-12-21
JP4535424B2 (ja) 2010-09-01
EP1414492A1 (de) 2004-05-06
WO2003004056A1 (en) 2003-01-16
NZ530099A (en) 2006-04-28
CN1551783A (zh) 2004-12-01
US7344715B2 (en) 2008-03-18
US7556803B2 (en) 2009-07-07
CN1551783B (zh) 2010-11-03
DE60223688T2 (de) 2008-10-30
US20080199463A1 (en) 2008-08-21
CA2461989A1 (en) 2003-01-16
US20040214761A1 (en) 2004-10-28
AU2006202148A1 (en) 2006-06-08
US20090263358A1 (en) 2009-10-22
ZA200400959B (en) 2005-04-26

Similar Documents

Publication Publication Date Title
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
DE60102016D1 (de) Verfahren zur behandlung von beweggungsstörungen
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60311368D1 (de) Verfahren zur Verbesserung der Effizienz der Behandlung von Silicium
DE60045416D1 (de) Verfahren zur behandlung von mikroelektroniksubstraten
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE60122839D1 (de) Verfahren zur Behandlung von chromatbelastetem Abwasser
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216514D1 (de) Verfahren zur behandlung von dämpferkondensat
ATE505811T1 (de) Verfahren zur nassbehandlung von scheibenförmigen gegenständen
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
ATA17552001A (de) Verfahren zur behandlung säurehältiger abwässer
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60217479D1 (de) Verfahren zur kontinuierlichen behandlung von wasser aus zahnärztlichen geräten
ATE493125T1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60104976D1 (de) Verfahren zur Bereitstellung von Dienstleistungen
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril

Legal Events

Date Code Title Description
8364 No opposition during term of opposition